Sign in
SCNI Stock Price, Chart, Stats & News
Scinai Immunotherapeutics Ltd.
Save
Scinai Immunotherapeutics Ltd. (SCNI) does not currently pay a dividend.
801,254
Market cap
–
Current P/E
–
Forward P/E
SCNI chart
Fundamentals
Gross margin | -114.38% |
Operating margin | -556.36% |
Pretax margin | -504.42% |
Net margin | -634.08% |
Effective tax rate | – |
ROA | -67.28% |
ROE | -89.26% |
D/E | 0.30x |
Interest coverage ratio | -29.94x |
SCNI valuation
P/E | – |
P/S | 0.63x |
P/B | 0.12x |
P/CF | -0.17x |
P/FCF | -0.14x |
P/OCF | -0.17x |
PEG | 0.00x |
EV multiple | 0.12x |
About
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen.
Similar securities
Based on sector and market capitalization
Report issue